在多发性骨髓瘤中CELMoD剂的作用
Niels W C J van de Donk1, Nizar J Bahlis2, Charlotte Pawlyn3,4
1Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
新的CELMoD药物伊贝尔多米德和梅齐多米德在治疗复发性或耐火性多发性骨髓瘤方面表现有前途. 这些向蛋白质降解剂可能为对当前疗法的耐药性患者提供新的选择.
科学领域:
- 癌症学
- 药理学
- 生物化学
背景情况:
- 多发性骨髓瘤在很大程度上是无法治愈的,大多数患者出现复发或抗治疗.
- 对于新疗法,特别是复发性或耐药性多发性骨髓瘤, 仍有不满足的需求.
- 有针对性的蛋白质降解是扩大可药物瘤点的有希望的方法.
研究的目的:
- 评估伊贝尔多米德和梅西格多米德作为多发性骨髓瘤新疗法的潜力.
- 在临床前模型中评估这些CELMoD药物的疗效,包括对现有疗法的耐药性.
- 探讨临床使用的伊伯多米德和梅西多米德的安全性和耐受性.
主要方法:
- 使用抗莱纳利多米德和抗利多米德细胞系进行临床前评估.
- 在多发性骨髓瘤小鼠模型中进行评估.
- 分析特异性,功效和安全性.
主要成果:
- 临床前数据表明,即使在对莱纳利多米德和波马利多米德耐药的模型中,伊伯多米德和梅西多米德也有效.
- 这些药物具有最佳的特异性,功效和安全性.
- 观察到与其他骨髓瘤疗法的协同作用.
结论:
- 伊伯多米德和梅西多米德是治疗复发性或耐火性多发性骨髓瘤的有前途的口服CELMOD药物.
- 伊伯多米德可能适用于早期治疗或维持治疗,而梅西多米德可能有利于早期复发或先前多次治疗的患者.
- 目前正在进行的临床试验正在评估这些药物,初步结果很有希望.
更多相关视频
07:24Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Differentiation of Common Myeloid Progenitor Cells
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mesenchymal Stem Cells
Treatment Resistant Cancers
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
